Dec. 1 (Bloomberg) -- WellPoint Inc., the largest U.S. health insurer by enrollment, won’t put Pfizer Inc.’s brand-name Lipitor drug on its generics list and will instead favor a copy made by Watson Pharmaceuticals Inc., Kristin Binns, a spokeswoman for the insurer, said in an e-mail.
Lipitor, the cholesterol medication that is Pfizer’s biggest product, began facing generic competition as of yesterday. The drugmaker has been making agreements with insurers and pharmacy benefit managers to favor its brand version and block generic competitors in return for price cuts.
To contact the reporter on this story: Drew Armstrong in New York at firstname.lastname@example.org
To contact the editor responsible for this story: Bruce Rule at email@example.com